Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
{{output}}
Background: With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events... ...
